INOSR Experimental Sciences 15(3):89-94, 2025. **ISSN: 2705-1692**
©INOSR PUBLICATIONS **INOSRES1530000**
International Network Organization for Scientific Research
https://doi.org/10.59298/INOSRES/2025/1538994

Nanoformulations of Polyphenols in Natural Products: A Dual Strategy against Obesity and Diabetic Complications

Nambi Namusisi H.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Obesity and diabetes mellitus are interlinked metabolic disorders with growing global prevalence and severe health consequences. Polyphenols, abundant in natural products, exhibit a wide range of pharmacological properties, including antioxidant, anti-inflammatory, and antidiabetic effects. However, their poor bioavailability and rapid metabolism hinder their therapeutic potential. Recent advances in nanotechnology have enabled the development of nanoformulations to enhance the delivery, stability, and efficacy of polyphenols. This review explores the dual role of polyphenol-based nanoformulations in combating obesity and diabetic complications. It highlights various types of nanocarriers, such as liposomes, nanoparticles, solid lipid nanoparticles (SLNs), and nanoemulsions, and their impact on enhancing the bioactivity of polyphenols. The article also delves into the molecular mechanisms through which nanoformulated polyphenols modulate adipogenesis, insulin resistance, inflammation, and oxidative stress. Finally, it discusses current limitations, regulatory concerns, and future perspectives in the clinical translation of polyphenol nanoformulations for metabolic disease management.

Keywords: Polyphenols, Nanoformulations, Obesity, Diabetes Mellitus, Natural Products, Nanoparticles, Insulin Resistance, Adipogenesis, Antioxidants,

INTRODUCTION

Obesity and diabetes mellitus have reached epidemic proportions globally, posing significant burdens on healthcare systems and economic productivity[1–3]. Obesity is defined by an excessive accumulation of body fat, typically resulting from a chronic imbalance between caloric intake and energy expenditure. On the other hand, diabetes mellitus, particularly type 2 diabetes is characterized by chronic hyperglycemia due to insulin resistance and/or impaired insulin secretion[4–6]. These two conditions are not only physiologically interconnected but also share common pathophysiological mechanisms, including oxidative stress, chronic low-grade inflammation, mitochondrial dysfunction, and altered lipid and glucose metabolism[7, 8]. Consequently, they frequently coexist within the framework of metabolic syndrome, amplifying the risk of cardiovascular complications, liver disease, and premature death. Lifestyle interventions and pharmacological agents offer some measure of control, but often fail to deliver long-term remission, thus creating a critical need for novel therapeutic strategies[9–12].

Among natural compounds, polyphenols have gained significant attention for their potential to modulate key metabolic pathways implicated in obesity and diabetes[13, 14]. Found abundantly in fruits, vegetables, whole grains, tea, and medicinal herbs, polyphenols such as resveratrol, curcumin, quercetin, and EGCG exhibit anti-inflammatory, antioxidant, and insulin-sensitizing effects[15–18]. However, despite their promise, translating these benefits into clinical success remains a challenge due to the poor solubility, chemical instability, and low systemic bioavailability of most polyphenols. These limitations significantly reduce their therapeutic efficacy when administered in conventional forms. In response to these challenges, nanotechnology has emerged as a transformative platform capable of enhancing the delivery, stability, and targeted activity of polyphenols. By encapsulating these bioactive compounds within nanoscale carriers, researchers are paving the way toward more effective interventions[19]. This review explores the dual potential of nanoformulated polyphenols in preventing and treating obesity and diabetes, with a critical focus on recent advancements, underlying molecular mechanisms, and translational implications.

Polyphenols in Natural Products: An Overview

Polyphenols represent a vast and structurally diverse class of secondary metabolites found predominantly in plant-based foods and medicinal herbs. These compounds are broadly classified into flavonoids (e.g., quercetin, catechins), phenolic acids (e.g., chlorogenic acid), stilbenes (e.g., resveratrol), and lignans (e.g., secoisolariciresinol)[20–23]. Each subclass possesses distinct structural features and biological activities, contributing to the wide range of health benefits associated with polyphenol-rich diets. For instance, EGCG from green tea exhibits potent antioxidant and anti-inflammatory effects, while curcumin from turmeric has been extensively studied for its antidiabetic and anti-obesity properties[24, 25]. Resveratrol, found in grapes and red wine, is known for its ability to activate sirtuin pathways, mimicking calorie restriction[15, 26]. Chlorogenic acid and quercetin also play vital roles in modulating glucose metabolism, lipid profiles, and oxidative stress responses. Collectively, these compounds interact with various signaling pathways involved in insulin sensitivity, lipid metabolism, and inflammatory regulation[17, 27–29].

Despite these promising effects, the clinical utility of polyphenols is significantly compromised by pharmacokinetic constraints. Most polyphenols exhibit poor water solubility, limiting their absorption through the gastrointestinal tract. Additionally, they are highly susceptible to enzymatic degradation in the digestive system and undergo extensive first-pass metabolism in the liver, resulting in a very low fraction of active compound reaching systemic circulation. The short biological half-life and rapid elimination of polyphenols further limit their therapeutic window[30]. Consequently, high doses are often required to achieve clinical efficacy, which may not be feasible or safe for long-term use. These challenges have driven a growing interest in advanced delivery systems, particularly nanotechnology-based platforms, that can protect polyphenols from degradation, enhance their absorption, and ensure targeted delivery to disease-affected tissues. Understanding the chemical nature and therapeutic roles of polyphenols is thus a crucial step toward optimizing their use in managing obesity and diabetes.

Limitations of Conventional Polyphenol Delivery

Despite extensive in vitro and animal model evidence supporting the health benefits of polyphenols, translating these findings into effective human therapies remains a significant challenge[31]. One of the primary obstacles is their low aqueous solubility, which hinders dissolution and absorption in the gastrointestinal tract. Most polyphenols are lipophilic and require carrier molecules or special formulations to facilitate uptake. Poor membrane permeability further limits their ability to cross biological barriers and reach intracellular targets[32]. Even when absorption occurs, polyphenols are prone to enzymatic degradation in the gut and undergo extensive first-pass metabolism in the liver, dramatically reducing the concentration of active metabolites in systemic circulation. Consequently, the actual bioavailability of polyphenols from dietary or supplement sources is often less than 5%, rendering their therapeutic effects minimal under conventional dosing strategies. Furthermore, polyphenols exhibit short biological half-lives, necessitating frequent dosing to maintain therapeutic plasma levels an impractical approach for chronic conditions like obesity and diabetes[33]. The rapid clearance of these compounds also contributes to inconsistent clinical outcomes, making it difficult to establish standard therapeutic regimens. Additionally, conventional formulations fail to offer controlled release, leading to peak-and-trough plasma concentrations that may reduce efficacy and increase side effects. These limitations highlight the urgent need for innovative delivery strategies that can protect polyphenols from degradation, enhance absorption and distribution, and allow for controlled and sustained release. Addressing these challenges is essential to unlocking the full therapeutic potential of polyphenols and moving toward more reliable, patient-friendly interventions for metabolic disorders.

Nanoformulation Strategies for Polyphenol Delivery

Nanotechnology provides a sophisticated toolkit for overcoming the pharmacokinetic barriers associated with conventional polyphenol delivery[6, 19]. By designing nanoscale carriers that can encapsulate, protect, and deliver polyphenols to specific tissues, researchers have made significant strides in enhancing bioavailability, stability, and therapeutic efficacy. Several nanoformulation strategies have been developed, each offering unique advantages. Liposomes, for example, are spherical vesicles made of phospholipid bilayers capable of encapsulating both hydrophilic and lipophilic compounds[34]. They enhance solubility, protect the encapsulated polyphenol from degradation, and offer controlled release, making them ideal for oral or intravenous administration. Solid lipid nanoparticles (SLNs) are another promising platform, composed of biocompatible lipids that remain solid at body temperature. SLNs provide a stable matrix that prevents chemical degradation and promotes intestinal uptake of polyphenols, particularly useful in combating gastrointestinal instability[6].

Polymeric nanoparticles, crafted from materials like PLGA, chitosan, and PEG, allow for precise control over drug release kinetics and targeted delivery. These particles can be engineered to respond to specific physiological triggers such as pH or temperature, ensuring site-specific release in the intestine or diseased tissue[35–37]. Nanoemulsions, typically oil-in-water emulsions, are designed to solubilize lipophilic polyphenols and improve their dispersibility in the aqueous environment of the gastrointestinal tract. This enhances absorption and facilitates lymphatic transport, bypassing first-pass metabolism. Nanomicelles and dendrimers, with their highly branched or colloidal structures, offer high drug-loading capacity and improved cellular uptake due to their small size and surface charge. These advanced nanoformulations are not only revolutionizing the delivery of

polyphenols but also opening new avenues for combination therapies, where multiple bioactives can be co-encapsulated to synergistically target obesity and diabetes[35]. Overall, nanotechnology holds the key to transforming polyphenols from promising natural compounds into clinically viable therapeutics.

Mechanisms of Action in Obesity and Diabetes

Nanoformulated polyphenols exert their anti-obesity and anti-diabetic effects through a multitude of cellular and molecular mechanisms that target key metabolic and inflammatory pathways[38]. One of the primary actions involves the anti-adipogenic effects of these compounds. Nanoencapsulation enhances the stability and cellular uptake of polyphenols, enabling them to more effectively downregulate adipogenic transcription factors such as peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer-binding protein alpha (C/EBPα), and sterol regulatory element-binding protein-1c (SREBP-1c)[11, 19]. These factors play pivotal roles in adipocyte differentiation and lipid storage. By suppressing their expression, nanoformulated polyphenols inhibit the formation of new fat cells and the accumulation of triglycerides, thereby preventing or reversing adipose tissue expansion commonly seen in obesity[30, 38].

In the context of diabetes, particularly type 2 diabetes mellitus (T2DM), nanoformulated polyphenols promote insulin sensitization through modulation of signaling pathways such as AMP-activated protein kinase (AMPK), phosphoinositide 3-kinase (PI3K)/Akt, and glucose transporter type 4 (GLUT4) translocation. AMPK activation enhances cellular energy balance and promotes glucose uptake, while PI3K/Akt signaling improves insulin responsiveness. Enhanced GLUT4 translocation to the plasma membrane allows more efficient glucose entry into cells, reducing hyperglycemia[14, 39]. Additionally, these compounds exhibit potent anti-inflammatory activity by downregulating pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), as well as inhibiting nuclear factor-kappa B (NF-κB) signaling. This reduces the chronic low-grade inflammation that contributes to insulin resistance. Furthermore, antioxidant effects are a vital component of the therapeutic action of nanoformulated polyphenols. Oxidative stress, characterized by excessive production of reactive oxygen species (ROS), plays a significant role in the pathogenesis of both obesity and diabetes. Polyphenols in their nanoformulated forms can directly scavenge ROS and enhance the expression and activity of endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). These actions help mitigate oxidative damage to pancreatic β-cells and insulin-sensitive tissues, preserving metabolic function[14]. Collectively, these multifaceted mechanisms demonstrate how nanoformulated polyphenols provide comprehensive protection against the metabolic dysfunctions associated with obesity and diabetes.

Preclinical and Clinical Evidence

A growing body of preclinical evidence supports the efficacy of nanoformulated polyphenols in mitigating obesity and diabetes-related complications.[14] Numerous in vitro studies have demonstrated the ability of these compounds to inhibit adipogenesis, reduce lipid accumulation, and enhance insulin signaling[14]. For instance, curcumin-loaded solid lipid nanoparticles (SLNs) have been shown to significantly improve glucose tolerance, reduce blood glucose levels, and diminish fat mass in obese murine models[25]. Similarly, epigallocatechin gallate (EGCG) nanoemulsions have exhibited potent anti-obesity effects, including reduced weight gain and adipocyte hypertrophy in rats fed a high-fat diet. These findings underscore the therapeutic potential of nanoencapsulated polyphenols to modulate metabolic pathways and reduce obesity-associated risk factors[24, 40].

In diabetic animal models, resveratrol-loaded nanoparticles have demonstrated improved pharmacokinetic profiles and enhanced bioactivity compared to their free-form counterparts[41]. These formulations have been shown to lower fasting blood glucose levels, enhance insulin sensitivity, and improve pancreatic β-cell function. Beyond rodent models, early-phase clinical trials in humans have yielded promising results. For example, trials using nano-curcumin and nano-quercetin formulations have reported improved glycemic control, reduced markers of oxidative stress, and better inflammatory profiles in patients with type 2 diabetes[41]. Despite these encouraging findings, these trials are generally limited by small sample sizes, short durations, and variability in dosage and delivery systems.

To truly assess the clinical utility of polyphenol-based nanotherapies, large-scale, randomized controlled trials (RCTs) are needed. These studies should evaluate long-term safety, efficacy, pharmacodynamics, and pharmacokinetics of various nanoformulated polyphenols in diverse populations. Additionally, standardization in formulation techniques, dosage regimens, and outcome measures will be critical for regulatory approval and clinical translation. Nonetheless, the available preclinical and early clinical evidence presents a compelling case for further investigation and development of nanoformulated polyphenols as novel therapeutic agents in obesity and diabetes management.

Challenges and Future Directions

Despite promising preclinical and preliminary clinical outcomes, several critical challenges must be addressed to enable the widespread adoption of nanoformulated polyphenols in clinical practice. One of the major concerns revolves around the toxicity and biocompatibility of nanocarriers. Some synthetic polymers or metallic nanoparticles used as delivery vehicles may elicit immune responses, accumulate in organs, or pose long-term toxicity risks. Ensuring the use of biodegradable, non-toxic, and biocompatible materials is crucial for minimizing adverse effects. Another challenge lies in the scale-up and manufacturing processes. Producing

nanocarriers with uniform size, stability, and consistent polyphenol loading at an industrial scale remains technically demanding and economically intensive.

Regulatory and ethical considerations also present significant hurdles. Nanomedicine is still a developing field, and the lack of harmonized regulations regarding safety testing, clinical evaluation, and labeling hampers the approval of nanoformulated therapeutics. Ethical concerns related to human trials, long-term exposure, and the environmental impact of nanomaterials must also be carefully addressed. Furthermore, there is a lack of standardized protocols for assessing the bioavailability, pharmacokinetics, and therapeutic efficacy of these nanoformulations. Without unified evaluation frameworks, comparing data across studies or gaining regulatory approval becomes challenging, delaying translation from research to real-world application.

Looking forward, future research should focus on the development of smart, stimuli-responsive nanocarriers that can release their payload in response to specific physiological conditions such as pH changes or inflammatory markers. This targeted approach would enhance therapeutic efficacy while minimizing systemic side effects. Additionally, the advent of personalized nanomedicine offers the potential to tailor nanoformulations based on individual genetic, metabolic, or microbiome profiles, thereby improving treatment outcomes. Advanced delivery methods, including oral, transdermal, and intranasal systems, are being explored to enhance patient compliance and bioavailability. Ultimately, collaborative efforts across disciplines, including nanotechnology, pharmacology, clinical medicine, and regulatory science, are essential to overcome current limitations and fully harness the potential of nanoformulated polyphenols in combating obesity and diabetes.

CONCLUSION

Nanoformulations of polyphenols offer a powerful dual approach to tackling obesity and diabetes by enhancing bioavailability and targeting multiple metabolic pathways. While promising, further research is needed to address current limitations and translate preclinical success into clinical practice. Harnessing the synergy between natural bioactive compounds and nanotechnology holds great promise in advancing metabolic disease therapeutics.

REFERENCES

1. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chem. X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233
2. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
3. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
4. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
5. Barber, T.M., Kyrou, I., Randeva, H.S., Weickert, M.O.: Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction. Int. J. Mol. Sci. 22, 546 (2021). https://doi.org/10.3390/ijms22020546
6. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
7. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Rotimi, S.O., Nna, V.U.: African walnuts (Tetracarpidium conophorum) modulate hepatic lipid accumulation in obesity via reciprocal actions on HMG-CoA reductase and paraoxonase. Endocr. Metab. Immune Disord.-Drug Targets Former. Curr. Drug Targets-Immune Endocr. Metab. Disord. 20, 365–379 (2020)
8. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Nna, V.U., Udeozor, P.A.: African walnuts attenuate ectopic fat accumulation and associated peroxidation and oxidative stress in monosodium glutamate-obese Wistar rats. Biomed. Pharmacother. Biomedicine Pharmacother. 124, 109879 (2020). https://doi.org/10.1016/j.biopha.2020.109879
9. Chaturvedi, S., Gupta, P.: Chapter 8 - Plant secondary metabolites for preferential targeting among various stressors of metabolic syndrome. In: Atta-ur-Rahman (ed.) Studies in Natural Products Chemistry. pp. 221–261. Elsevier (2021)
10. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
11. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086

12. Alum, E.U., Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diab. Vasc. Dis. Res. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
13. Ahmad, K., Shaikh, S., Lim, J.H., Ahmad, S.S., Chun, H.J., Lee, E.J., Choi, I.: Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective. Biomed. Pharmacother. 168, 115642 (2023). https://doi.org/10.1016/j.biopha.2023.115642
14. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
15. Li, Z., Zhang, Z., Ke, L., Sun, Y., Li, W., Feng, X., Zhu, W., Chen, S.: Resveratrol promotes white adipocytes browning and improves metabolic disorders in Sirt1-dependent manner in mice. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 34, 4527–4539 (2020). https://doi.org/10.1096/fj.201902222R
16. Peng, Y., Ao, M., Dong, B., Jiang, Y., Yu, L., Chen, Z., Hu, C., Xu, R.: Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures. Drug Des. Devel. Ther. 15, 4503–4525 (2021). https://doi.org/10.2147/DDDT.S327378
17. Chiang, M.-C., Tsai, T.-Y., Wang, C.-J.: The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms. Int. J. Mol. Sci. 24, 6328 (2023). https://doi.org/10.3390/ijms24076328
18. Markowska, J., Kasprzak-Drozd, K., Niziński, P., Dragan, M., Kondracka, A., Gondek, E., Oniszczuk, T., Oniszczuk, A.: Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Molecules. 29, 5245 (2024). https://doi.org/10.3390/molecules29225245
19. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
20. Alami, M., Boumezough, K., Zerif, E., Zoubdane, N., Khalil, A., Bunt, T., Laurent, B., Witkowski, J.M., Ramassamy, C., Boulbaroud, S., Fulop, T., Berrougui, H.: In Vitro Assessment of the Neuroprotective Effects of Pomegranate (Punica granatum L.) Polyphenols Against Tau Phosphorylation, Neuroinflammation, and Oxidative Stress. Nutrients. 16, 3667 (2024). https://doi.org/10.3390/nu16213667
21. Bié, J., Sepodes, B., Fernandes, P.C.B., Ribeiro, M.H.L.: Polyphenols in Health and Disease: Gut Microbiota, Bioaccessibility, and Bioavailability. Compounds. 3, 40–72 (2023). https://doi.org/10.3390/compounds3010005
22. Alum, E.U., Udechukwu, C.D., Obasi, D.C.: RNA signaling in medicinal plants: An overlooked mechanism for phytochemical regulation. Biochem. Biophys. Rep. 42, 102032 (2025). https://doi.org/10.1016/j.bbrep.2025.102032
23. Berenshtein, L., Okun, Z., Shpigelman, A.: Stability and Bioaccessibility of Lignans in Food Products. ACS Omega. 9, 2022–2031 (2024). https://doi.org/10.1021/acsomega.3c07636
24. Mokra, D., Joskova, M., Mokry, J.: Therapeutic Effects of Green Tea Polyphenol (–)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis. Int. J. Mol. Sci. 24, 340 (2022). https://doi.org/10.3390/ijms24010340
25. El-Saadony, M.T., Yang, T., Korma, S.A., Sitohy, M., Abd El-Mageed, T.A., Selim, S., Al Jaouni, S.K., Salem, H.M., Mahmmod, Y., Soliman, S.M., Mo'men, S.A.A., Mosa, W.F.A., El-Wafai, N.A., Abou-Aly, H.E., Sitohy, B., Abd El-Hack, M.E., El-Tarabily, K.A., Saad, A.M.: Impacts of turmeric and its principal bioactive curcumin on human health: Pharmaceutical, medicinal, and food applications: A comprehensive review. Front. Nutr. 9, 1040259 (2023). https://doi.org/10.3389/fnut.2022.1040259
26. Mahjabeen, W., Khan, D.A., Mirza, S.A.: Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial. Complement. Ther. Med. 66, 102819 (2022). https://doi.org/10.1016/j.ctim.2022.102819
27. Kanchanasurakit, S., Saokaew, S., Phisalprapa, P., Duangjai, A.: Chlorogenic acid in green bean coffee on body weight: a systematic review and meta-analysis of randomized controlled trials. Syst. Rev. 12, 163 (2023). https://doi.org/10.1186/s13643-023-02311-4
28. Wang, L., Pan, X., Jiang, L., Chu, Y., Gao, S., Jiang, X., Zhang, Y., Chen, Y., Luo, S., Peng, C.: The Biological Activity Mechanism of Chlorogenic Acid and Its Applications in Food Industry: A Review. Front. Nutr. 9, (2022). https://doi.org/10.3389/fnut.2022.943911
29. Alum, E.U.: Role of phytochemicals in cardiovascular disease management: Insights into mechanisms, efficacy, and clinical application. Phytomedicine Plus. 5, 100695 (2025). https://doi.org/10.1016/j.phyplu.2024.100695

30. Sichetti, M., Giuseffi, M., Giglio, E., Marino, G., Mecca, M.: Effect of Natural Polyphenols on Breast Cancer Chemoprevention and Treatment. Mol. Nutr. Food Res. n/a, e70055. https://doi.org/10.1002/mnfr.70055
31. Vauzour, D., Rodriguez-Mateos, A., Corona, G., Oruna-Concha, M.J., Spencer, J.P.E.: Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action. Nutrients. 2, 1106–1131 (2010). https://doi.org/10.3390/nu2111106
32. Alum, E.U.: Priming medicinal plants with stress signals: a sustainable approach to boosting therapeutic efficacy. J. Plant Interact. 20, 2500947 (2025). https://doi.org/10.1080/17429145.2025.2500947
33. Feldman, F., Koudoufio, M., Desjardins, Y., Spahis, S., Delvin, E., Levy, E.: Efficacy of Polyphenols in the Management of Dyslipidemia: A Focus on Clinical Studies. Nutrients. 13, 672 (2021). https://doi.org/10.3390/nu13020672
34. Enzyme-responsive liposomes for controlled drug release. | Semantic Scholar, https://www.semanticscholar.org/paper/Enzyme-responsive-liposomes-for-controlled-drug-Wei-Lv/b1d010ba3c8440075ad2d08a613991904f4bdf7a
35. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
36. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
37. Wang, X.-Q., Zhang, Q.: pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 82, 219–229 (2012). https://doi.org/10.1016/j.ejpb.2012.07.014
38. He, L., Su, Z., Wang, S.: The anti-obesity effects of polyphenols: a comprehensive review of molecular mechanisms and signal pathways in regulating adipocytes. Front. Nutr. 11, 1393575 (2024). https://doi.org/10.3389/fnut.2024.1393575
39. Adhikari, B.: Roles of Alkaloids from Medicinal Plants in the Management of Diabetes Mellitus. J. Chem. 2021, 2691525 (2021). https://doi.org/10.1155/2021/2691525
40. James, A., Wang, K., Wang, Y.: Therapeutic Activity of Green Tea Epigallocatechin-3-Gallate on Metabolic Diseases and Non-Alcoholic Fatty Liver Diseases: The Current Updates. Nutrients. 15, 3022 (2023). https://doi.org/10.3390/nu15133022
41. Salla, M., Karaki, N., El Kaderi, B., Ayoub, A.J., Younes, S., Abou Chahla, M.N., Baksh, S., El Khatib, S.: Enhancing the Bioavailability of Resveratrol: Combine It, Derivatize It, or Encapsulate It? Pharmaceutics. 16, 569 (2024). https://doi.org/10.3390/pharmaceutics16040569

CITE AS: Nambi Namusisi H. (2025). Nanoformulations of Polyphenols in Natural Products: A Dual Strategy against Obesity and Diabetic Complications. INOSR Experimental Sciences 15(3):89-94. https://doi.org/10.59298/INOSRES/2025/1538994